CD4
+ lymphopenia is a common hallmark of both idiopathic CD4 + lymphopenia (ICL) and human immunodeficiency virus (HIV) infection, leading to opportunistic infections. In HIV infection, a profound CD4 + T-cell depletion occurs in the gut very early in primary infection to a greater extent than in blood [1] . This depletion occurs both in humans and in nonhuman primate models, with a predominant depletion of memory CCR5 CD4 + T cells [2] and of the T-helper type 17 (Th17) subset among CD4 + T cells [3] .
Chronic immune activation is another hallmark of HIV infection, and the levels of activated T lymphocytes correlate with the progression of the disease in untreated HIV type 1 (HIV)-infected patients [4] . In this report, Kovacs et al [7] described the extent of CD4 + T-cell lymphopenia developing in the colonic mucosa of patients with ICL. Focusing on the gut mucosa is, indeed, a crucial point since gut-associated mucosa has been considered a major site of CD4 + T-cell accumulation. The authors provide evidence of T-cell depletion in the colonic mucosa of the patients with this rare syndrome. Their results are supported by a large number of patients studied, despite the rarity of the syndrome. Compared with healthy controls, they found depletion of CD4 + and CD8 + T cells in patients with
ICL. This decrease of T cells in the gut did not seem to be related to a homing defect, as the expression of the integrin β7 was not different, compared with healthy controls. However, the proportions of T-cell subsets and those of naive, central memory, and effector memory CD4 + T-cell subsets were preserved in the colon (contrasting with blood). The authors looked for functional alterations of the CD4 + T-cell subsets, especially the Th1 and Th17 subsets. They found that the proportion of mucosal CD4 + T cells producing IL-17 was higher in patients with ICL, compared with healthy controls, suggesting that the Th17 subset is preserved in patients with ICL and seems to be functional. Treg proportions were not different between patients with ICL and healthy controls, but the functionality of the Treg subset was not tested. As the Th17 subset is strongly involved in the homeostasis of the mucosal barrier, the authors looked for evidence of mucosal damage. However, they did not find evidence of alterations of the gut epithelium: fatty acid-binding protein and LPS levels were not significantly increased, compared with controls. Levels of the inflammatory cytokines interleukin 6 and tumor necrosis factor α were also not increased. Interestingly, an enrichment of macrophages and polymorphonuclear cells was shown, which could be the explanation of the increase of soluble CD14 (sCD14) levels. Although this study provides meaningful information, the role of other non-T-cell partners present in the gut (eg, macrophages, innate lymphoid cells, and γδ T cells) remains to be investigated in ICL (and in HIV infection). A recruitment of γδ T cells, in combination with Th17 cells, could also provide protection against pathogens in some of these patients. These results showed that, in ICL, there is a quantitative depletion of CD4 + T cells in the gut but that the Th17 CD4 + cell subset seems to be preserved. This observation strengthens the notion that CD4 + T-cell lymphopenia per se does not directly induce gut pathophysiology, an observation that is reminiscent of previous reports in nonpathogenic simian immunodeficiency virus (SIV)-infected macaque models [14, 15] . In ICL, CD4 + T-cell depletion is not sufficient to induce a strong proinflammatory state, suggesting that the depletion of the Th17 subset is probably much more deleterious and may constitute a key event at the origin of chronic inflammation. Alternately, it is tempting to speculate that, more than the number, it is the functional equilibrium between Th1, Th17, and Tregs that ensures efficient mucosal homeostasis. These results provide novel information about the pathogenesis of ICL and, perhaps indirectly, are relevant to HIV infection, as well. In ICL, the Kovacs et al study raises questions regarding the mechanisms responsible for chronic immune activation associated with CD4 + T-cell lymphopenia. Alterations of the gut mucosa do not appear to be strongly involved. It would be interesting to determine the nature of CD4 + T-cell lymphopenia developing in other lymphoid or nonlymphoid sites. In the context of HIV infection, these observations emphasize the crucial need to preserve or restore the Th17 cell subset. Preserving the Th17 subset may reduce microbial translocation and, as a consequence, the chronic inflammation involved in CD4 + T-cell dysfunction. Interestingly, several recent reports support such a strategy. ART initiated very early in primary infection seems to preserve mucosal Th17 function and reverses HIV-related immune activation [16] . In a model of SIV-infected macaques, interleukin 21 preserved Th17 cells, leading to reduced levels of intestinal T-cell proliferation, microbial translocation, and systemic activation/inflammation in chronically infected animals [17] . Microbiota in HIVinfected patients are disturbed [18] . Strategies aiming at the restoration of normal microbiota in the gut of HIV-infected patients are promising and should be pursued [19] .
